Actinogen Medical targets key FY27 catalysts

Actinogen Medical CFO Will Souter talked with Proactive about the company’s FY2026 milestones, its upcoming XanaMIA Alzheimer’s disease trial results in November, and the priorities that could shape its progress through FY2027. Souter said the past year had been significant for Actinogen Medical, with the current Alzheimer’s disease study nearing completion after several years of work. “It’s been a big journey and the guys have done an amazing job to bring it all the way to the conclusion that’s just around the corner with results in November. Alongside progress with XanaMIA, Souter highlighted regulatory alignment with both the US Food and Drug Administration and the European Medicines Agency. He said this had provided the company with clear guidance on the steps required following the November results. Actinogen Medical also published a journal article during the year highlighting activity of its molecule in patients with depression. Souter also discussed the company’s financial position and spending priorities. He said most expenditure had been directed toward eligible research and development activities, resulting in an anticipated R&D rebate of nearly $11 million. Combined with a pro forma cash balance of just under $17 million at June 30, he said the company was positioned to respond to the November trial results and move into planned activities during 2027, with funding extending to mid-2027 and beyond. A stronger balance sheet could also support potential partnership discussions following the trial readout. Souter said Actinogen Medical’s three key objectives were to successfully complete XanaMIA and deliver a high-quality final data set in November, continue regulatory and clinical planning for a final pivotal trial in 2027, and prepare for potential discussions with global partners if the results are successful. Visit Proactive’s YouTube channel for more interviews and market updates. If you found this video useful, give it a like, subscribe to the channel and enable notifications for future content.